The Pulmonary Fibrosis Drug market is a subset of the larger Respiratory Drugs market. It is composed of drugs used to treat pulmonary fibrosis, a chronic and progressive lung disease. These drugs are used to reduce symptoms, slow the progression of the disease, and improve quality of life. Common treatments include corticosteroids, immunosuppressants, and antifibrotic agents. In some cases, lung transplantation may be recommended. The Pulmonary Fibrosis Drug market is highly competitive, with many companies developing and marketing treatments. Some of these companies include Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Novartis, and Vertex Pharmaceuticals. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.